EUVIMEDEUVIMED entdecken
Crossref

ERα prevents tumorigenesis of both liver and breast cancer cells through CCN5

Daoshan Zheng, Muniba Bashir, Zhaoyu Li

Biochemical and Biophysical Research Communications · 2023

DOI: 10.1016/j.bbrc.2023.06.018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2023. Verfasst von Daoshan Zheng und 2 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Ministry of Education for Gastrointestinal Cancer, School of Basic Medical Sciences, Fujian Medical University, No. 1 Xuefu North R…. Hauptthemen laut MEDLINE: Breast Neoplasms, Liver Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: NCI NIH HHS, University of Western Australia, National Computational Infrastructure.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Estrogen receptor alpha (ERα)-mediated estrogen signaling has also shown to prevent hepatic tumorigenesis in mice. Consistent with this, hormone replacement therapy with estrogen supplementation dramatically reduced the risk of hepatocellular carcinoma. Silencing of ERα is also a key event for the transformation of ERα-positive breast cancer cells into malignant triple-negative breast cancer cells. However, the mechanisms underlying ERα-mediated prevention of both hepatic and mammary tumorigenesis in humans are still unclear. Here, we present a functional genomics study of ERα targeting by comparing human liver cancer cells with human breast cancer cells using "loss or gain of function" genetic assays of ERα in vitro and in vivo. We discover that cellular communication network factor 5 (CCN5) is a direct downstream target of ERα; ERα suppresses growth and prevents tumorigenesis and malignant transformation of both liver and breast cancer cells through CCN5 in humans. The ERα-CCN5 regulatory axis functions as suppressors for both hepatic and mammary tumors, which is a common mechanism of preventing tumorigenesis for both liver cancer and breast cancer in humans.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsLiver NeoplasmsAnimalsFemaleHumansMiceCarcinogenesisCell Transformation, NeoplasticEstrogen Receptor alphaEstrogensRepressor ProteinsCCN Intercellular Signaling Proteins

Stichwörter der Autor:innen

And tumorigenesisCCN5ERα

Substanzen

Estrogen Receptor alphaEstrogensCCN5 protein, humanRepressor ProteinsCCN Intercellular Signaling Proteins

Autor:innen und Institutionen

  • Key Laboratory of Ministry of Education for Gastrointestinal Cancer, School of Basic Medical Sciences, Fujian Medical University, No. 1 Xuefu North Road, University Town, Fuzhou, Fujian Province, 350112, China.
  • School of Biomedical Sciences, University of Western Australia, QE II, M Block 225C, Crawley, WA, 6009, Australia.
  • School of Biomedical Sciences, University of Western Australia, QE II, M Block 225C, Crawley, WA, 6009, Australia. Electronic address: zhaoyu.li@uwa.edu.au.

Förderung

  • NCI NIH HHS
  • University of Western Australia
  • National Computational Infrastructure

Zitieren

APA

Zheng, D., Bashir, M., & Li, Z. (2023). ERα prevents tumorigenesis of both liver and breast cancer cells through CCN5. Biochemical and Biophysical Research Communications. https://doi.org/10.1016/j.bbrc.2023.06.018

Vancouver

Zheng D, Bashir M, Li Z. ERα prevents tumorigenesis of both liver and breast cancer cells through CCN5. Biochemical and Biophysical Research Communications. 2023. doi:10.1016/j.bbrc.2023.06.018

BibTeX
@article{Zheng2023,
  author = {Zheng, Daoshan and Bashir, Muniba and Li, Zhaoyu},
  title = {ERα prevents tumorigenesis of both liver and breast cancer cells through CCN5},
  journal = {Biochemical and Biophysical Research Communications},
  year = {2023},
  doi = {10.1016/j.bbrc.2023.06.018}
}
Kostenlos starten →